A pooled analysis from three basket trials (ALKA, STARTRK-1, and STARTRK-2) testing another TRK inhibitor, entrectinib, in TRK fusion–positive cancers demonstrated similar results, with an ORR of 61% (92 of 150 patients) and 17 tumor types represented (Krzakowski et al. 2022). This evidence concerns the gene NTRK1 and neoplasm.